This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / REGENXBIO Faces Class Action Lawsuit
Business class action lawsuit

REGENXBIO Faces Class Action Lawsuit

Analysis based on 15 articles · First reported Feb 16, 2026 · Last updated Feb 20, 2026

Sentiment
-20
Attention
2
Articles
15
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the news of REGENXBIO's drug candidates being placed on clinical hold, leading to a significant drop in REGENXBIO's stock price. This event highlights the risks associated with clinical-stage biotechnology companies and the importance of regulatory oversight.

Biotechnology Legal Services
Event Summary

Robbins LLP has filed a class action lawsuit against REGENXBIO, a clinical-stage biotechnology company, on behalf of investors who purchased its securities between February 9, 2022, and January 27, 2026. The lawsuit alleges that REGENXBIO misled investors regarding the safety and viability of its lead clinical-stage gene therapy candidate, RGX-111, for the treatment of MPS I. Despite repeatedly touting positive interim safety and biomarker data, REGENXBIO was allegedly aware of serious safety issues, including the potential for CNS neoplasm. In November 2023, REGENXBIO de-prioritized RGX-111, and on January 28, 2026, the United States===Food and Drug Administration placed a clinical hold on RGX-111 and RGX-121 due to a case of neoplasm. This news caused REGENXBIO's stock price to decline by 17.8% in a single day.

Key Actions
100 Robbins LLP filed a class action lawsuit REGENXBIO
90 United States===Food and Drug Administration placed a clinical hold on investigational gene therapies REGENXBIO
70 REGENXBIO de-prioritized its second-most advanced clinical candidate
Entities Involved
stock
REGENXBIO
REGENXBIO is facing a class action lawsuit for allegedly misleading investors about the viability of its drug candidate RGX-111. The FDA placed a clinical hold on RGX-111 and RGX-121 due to safety concerns, leading to a significant drop in REGENXBIO's stock price.
Importance 100 Sentiment -70
govactor
United States===Food and Drug Administration
The United States===Food and Drug Administration placed a clinical hold on REGENXBIO's investigational gene therapies RGX-111 and RGX-121 due to a case of neoplasm in a participant treated with RGX-111.
Importance 80 Sentiment 0
priv
Robbins LLP
Robbins LLP filed a class action lawsuit against REGENXBIO on behalf of investors who purchased REGENXBIO securities. They are investigating allegations that REGENXBIO misled investors regarding its drug candidate RGX-111.
Importance 70 Sentiment 20
per
Aaron Dumas Jr.
Aaron Dumas, Jr. is an attorney at Robbins LLP and is listed as a contact for the class action lawsuit against REGENXBIO.
Importance 10 Sentiment 0
Relationships
REGENXBIO related ↔ Robbins LLP
REGENXBIO related ↔ United States===Food and Drug Administration
Robbins LLP related ↔ United States===Food and Drug Administration
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.